Concert Pharmaceuticals Inc., of Lexington, Mass., appointed Justine E. Koenigsberg senior director of corporate communications and investor relations.

Cylex Inc., of Columbia, Md., appointed Brad L. Stewart president.

Echo Therapeutics, of Franklin, Mass., named Anthony P. Furnary to its medical advisory board.

Egenix Inc., of New York, appointed Donald C. Fresne chairman and CEO and named Daniel Petrylak chairman of its scientific advisory board.

Elite Pharmaceuticals Inc., of Northvale, N.J., appointed Stuart Apfel chief scientific officer.

ExonHit Therapeutics SA, of Paris, elected Frederic Desdouits to its supervisory board and appointed Patrick Langlois as vice chairman of the board.

Gene Network Sciences Inc., of Cambridge, Mass., named James Collins chief scientific officer and co-chair of the scientific advisory board. It also appointed SAB members Jeffrey Besterman, Jeffrey Hanke, Stuart Kaufmann, Hiroaki Kitano, Christophe Lengauer, Matej Oresic and Hans Winkler.

Genelabs Technologies Inc., of Redwood City, Calif., appointed Amy K. Patrick vice president of biological sciences.

GeneNews Ltd., of Toronto, elected Harry A. Glorikian and Fran Tuttle to its board.

Gilead Sciences Inc., of Foster City, Calif., appointed John C. Martin chairman and named John F. Milligan president.

GTx Inc., of Memphis, Tenn., appointed Kenneth S. Robinson to its board.

Helix BioPharma Corp., of Aurora, Ontario, appointed W. Thomas Hodgson to its board.

Histogen Inc., of San Diego, named Craig Ziering to its scientific advisory board.

Human Genome Sciences Inc., of Rockville, Md., appointed John L. LaMattina to its board.

Hyperion Therapeutics Inc., of South San Francisco, named Bruce F. Scharschmidt chief medical officer.

ImmuneRegen BioSciences Inc., of Scottsdale, Ariz., appointed Ivan N. Rich to its advisory board.

Inflazyme Pharmaceuticals Ltd., of Vancouver, British Columbia, appointed Alan Savage to its board.

Innate Pharma SA, of Marseille, France, named Hemanshu Shah executive vice president and chief business officer for U.S. operations.

InSite Vision Inc., of Alameda, Calif., named Surendra Patel vice president of operations.

Interleukin Genetics Inc., of Waltham, Mass., appointed Eliot M. Lurier chief financial officer.

KaloBios Pharmaceuticals Inc., of Palo Alto, Calif., named Jeanne Y. Jew head of pharmaceutical business development and Thomas C. Yonker head of project management.

Labopharm Inc., of Laval, Quebec, appointed Claire Brulle senior vice president and chief medical officer.

LifeCycle Pharma A/S, of Horsholm, Denmark, appointed Karin Hamberg executive vice president of research and development.

Light Sciences Oncology Inc., of Bellevue, Wash., appointed David P. Holveck to its board.

Lorus Therapeutics Inc., of Toronto, appointed Saeid Babaei vice president of business development and Yoon Lee vice president of research.